+177.9%
MXL vs GSK
+198.3%
-20.4%
-88.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.8% | -0.1% | -6.8% | -6.8% |
| 7D | -7.0% | -1.3% | -5.7% | -6.7% |
| 30D | -27.1% | +2.7% | -29.9% | -28.1% |
| 3M | -38.7% | +2.7% | -41.5% | -40.1% |
| 6M | -43.7% | +3.3% | -47.0% | -45.8% |
| YTD | +198.2% | +6.5% | +191.7% | +176.1% |
| 1Y | +273.9% | +10.7% | +263.2% | +239.4% |
| 3Y | +195.8% | +64.4% | +131.4% | +103.3% |
| 5Y | -27.7% | +46.7% | -74.4% | -48.6% |
| 10Y | +145.0% | +109.4% | +35.7% | +33.0% |
| All | +177.9% | +198.3% | -20.4% | +0.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling